期刊
PHARMACOGENOMICS
卷 16, 期 15, 页码 1723-1731出版社
FUTURE MEDICINE LTD
DOI: 10.2217/pgs.15.107
关键词
adalimumab; etanercept; IL-17; infliximab; pharmacogenetics; psoriasis; rs763780; rs10484879; rs2275913; ustekinumab
资金
- Universidad Autonoma de Madrid (FPI program)
- AbbVie (Abbott)
- Amgen
- Janssen-Cilag
- Leo Pharma
- Novartis
- Pfizer
- MSD
- Celgene
- Abbott
- Alter
- Chemo
- Farmalider
- Ferrer
- GlaxoSmithKline
- Kern
- Normon
- Servier
- Teva
- Zambon
- Astellas
- Gebro
- Isdin
- Lilly
- Instituto de Salud Carlos III [FIS PI10/01740]
- Fundacion Teofilo Hernando
- AbbVie
Psoriasis improves when IL-17 is blocked. Anti-TNF drugs reduce the IL-17 signaling pathway, and anti-IL-17 drugs are being developed to treat moderate-to-severe psoriasis. We analyzed three SNPs in IL-17A (rs2275913 and rs10484879) and IL-17F (rs763780) to look for an association with psoriasis and/or with response to anti-TNF drugs or ustekinumab. We included 197 healthy controls and 194 patients with moderate-to-severe psoriasis. The results of the univariate analysis showed an association between rs10484879 and psoriasis, although this relationship disappeared after adjustment for HLA-C (rs12191877). We also found an association between rs763780 (IL-17F) and response to ustekinumab (n = 70) and infliximab (n = 37) at 3 and 6 months and an association between rs763780 and the response to adalimumab at 6 months (n = 67).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据